NCT01995617View on ClinicalTrials.gov

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Streptococcus Pneumoniae
Interventions
BIOLOGICAL

Placebo

normal saline, 0.5 mL per dose

BIOLOGICAL

GEN-004 Low Dose

The GEN-004 Low Dose contains 10µg of each of the three antigens.

BIOLOGICAL

GEN-004 Low Dose + Adjuvant

The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

BIOLOGICAL

GEN-004 Mid Dose

The GEN-004 Mid Dose contains 30µg of each of the three antigens.

BIOLOGICAL

GEN-004 Mid Dose + Adjuvant

The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

BIOLOGICAL

GEN-004 High Dose

The GEN-004 High Dose contains 100µg of each of the three antigens.

BIOLOGICAL

GEN-004 High Dose + Adjuvant

The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

Trial Locations (1)

55114

Prism Research, Saint Paul

Sponsors
All Listed Sponsors
lead

Genocea Biosciences, Inc.

INDUSTRY